{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:22:53Z","timestamp":1784935373433,"version":"3.55.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hereditary transthyretin amyloidosis (hATTR) is a rare cause of severe neuropathy, typically with progressive sensorimotor and autonomic manifestations. The clinical course is marked by progressive worsening with typical survival of 7\u201311 years following the onset of symptoms. The phenotype may resemble other types of neuropathy, and dysautonomia may be absent at onset delaying the diagnosis. Two medications were recently approved for treatment of hATTR neuropathy in the United States and more may follow. Three major phenotypes of hATTR include neuropathic, cardiac, and mixed. Diagnostic clues include \u201cred-flag\u201d symptoms reflecting typical multisystem involvement, often presenting with cardiomyopathy, gastrointestinal dysmotility, or kidney insufficiency. We present a case series of 4 patients with late-onset hATTR neuropathy who were initially diagnosed with vasculitic neuropathy and chronic inflammatory demyelinating polyneuropathy to illustrate diagnostic challenges encountered with hATTR. Early diagnosis is even more urgent now given the availability of disease modifying treatments.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000252","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T06:51:43Z","timestamp":1566888703000},"page":"1-6","source":"Crossref","is-referenced-by-count":7,"title":["Phenotypes of Late-Onset Transthyretin Amyloid Neuropathy: A Diagnostic Challenge"],"prefix":"10.1097","volume":"21","author":[{"given":"Sa\u0161a A.","family":"\u017divkovi\u0107","sequence":"first","affiliation":[{"name":"Department of Neurology, UPMC, Pittsburgh, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mnatsakanova","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation, University of Illinois, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lacomis","sequence":"additional","affiliation":[{"name":"Department of Neurology, UPMC, Pittsburgh, PA;"},{"name":"Department of Pathology (Neuropathology), UPMC, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med."},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Conceicao","year":"2016","journal-title":"J Peripher Nerv Syst."},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"Plante-Bordeneuve","year":"2007","journal-title":"Neurology."},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve."},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13506129.2011.565524","article-title":"Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis","volume":"18","author":"Koike","year":"2011","journal-title":"Amyloid."},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1474-4422(16)30231-9","article-title":"Carpal tunnel syndrome: clinical features, diagnosis, and management","volume":"15","author":"Padua","year":"2016","journal-title":"Lancet Neurol."},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology."},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J."},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/mus.24563","article-title":"Amyloid polyneuropathy caused by wild-type transthyretin","volume":"52","author":"Lam","year":"2015","journal-title":"Muscle Nerve."},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA."},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 Years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation."},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med."},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med."},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40120-015-0031-3","article-title":"A review of tafamidis for the treatment of transthyretin-related amyloidosis","volume":"4","author":"Waddington Cruz","year":"2015","journal-title":"Neurol Ther."},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8027.2010.00245.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014First Revision","volume":"15","year":"2010","journal-title":"J Peripher Nerv Syst."},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","article-title":"Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy","volume":"91","author":"Lozeron","year":"2018","journal-title":"Neurology."},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani","year":"2015","journal-title":"Ann Neurol."},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev."},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation."},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0022-510X(93)90025-T","article-title":"Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis","volume":"120","author":"Simmons","year":"1993","journal-title":"J Neurol Sci."},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archneurol.2010.261","article-title":"Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue","volume":"68","author":"Klein","year":"2011","journal-title":"Arch Neurol."},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4065\/83.11.1226","article-title":"Patterns of neuropathy and autonomic failure in patients with amyloidosis","volume":"83","author":"Wang","year":"2008","journal-title":"Mayo Clin Proc."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T05:14:17Z","timestamp":1693631657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000252","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}